Nkarta (NKTX) Asset Writedowns and Impairment (2023 - 2025)
Nkarta's (NKTX) quarterly Asset Writedowns and Impairment came in at $791000.0 in Q3 2025, down 80.71% quarter-over-quarter from $4.1 million in Q2 2023.
Nkarta (NKTX) Asset Writedowns and Impairment (2023 - 2025) Analysis & Trends
Nkarta's Asset Writedowns and Impairment history runs 2 years deep, the most recent figure standing at $791000.0 for Q3 2025.
- On a quarterly basis, Asset Writedowns and Impairment changed N/A year-over-year to $791000.0 in Q3 2025; TTM through Dec 2025 was $791000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $791000.0, changed N/A from the prior year.
- Asset Writedowns and Impairment slipped to $791000.0 in Q3 2025 per NKTX's latest filing, from $4.1 million in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $4.1 million in Q2 2023 and bottomed at $791000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - |
| 4 | BeOne Medicines | 471.62 Bn | 466.83 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.97 Bn | 114.72 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.98 Bn | 61.22 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - |
| 8 | Argenx Se | 55.75 Bn | 50.57 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn |
| 10 | Nkarta | 171.54 Mn | 171.54 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 791,000.00 |
| Sep 30, 2025 | 791,000.00 |
| Jun 30, 2023 | 4.10 Mn |
| Jun 30, 2023 | 4.10 Mn |